StemCell Therapy

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device. REBUILD met the criteria set by the FDA for Breakthrough Devices, potentially providing a novel treatment of an often irreversibly debilitating condition: incisional hernia. Less than 7% of Breakthrough Devices are in the field of general surgery, making REBUILD a standout product in a sector of medicine struggling to make profound advances.

See the rest here:
AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device

This entry was posted on January 25, 2024 at 2:42 am and is filed under Global News Feed. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |